Sleeve lobectomy after neoadjuvant therapy for non-small cell lung cancer
Official title: Comparative Analysis of Minimally Invasive and Open Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC: A Multicenter Retrospective Evaluation of Surgical Outcomes
Run by Shanghai Chest Hospital · NCT07135856 · Data updated 2026-11-12
This will see if minimally invasive sleeve lobectomy (VATS or RATS) works as well or better than open thoracotomy for adults with non-small cell lung cancer who received pre-surgery (neoadjuvant) treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | November 1, 2025 |
| Study ends | December 1, 2026 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07135856 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed non-small cell lung cancer who received neoadjuvant therapy and underwent sleeve lobectomy with curative intent at a participating center, with complete perioperative records and at least 12 months of follow-up, are the ideal candidates for inclusion.
✕Probably not a fit
Patients with metastatic (stage IV) disease, those who had sublobar resections or pneumonectomy, those who did not receive neoadjuvant therapy, or those with incomplete records or lost follow-up are unlikely to benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, multicenter cohort study collecting surgical and oncologic outcomes from adults with NSCLC who received neoadjuvant therapy and underwent sleeve lobectomy. The analysis compares minimally invasive approaches (VATS or RATS) to open thoracotomy for perioperative and postoperative metrics such as complications, operative complexity, and length of stay. Oncologic endpoints include margin status, extent of lymph node dissection, recurrence-free survival, and overall survival with a minimum 12-month follow-up or until death. Data are pooled from high-volume thoracic centers including Shanghai Chest Hospital and collaborating hospitals to clarify whether minimally invasive techniques provide comparable safety and cancer control in the context of modern multimodal therapy.
Why it matters
Potential benefit: If successful, the findings could support wider use of minimally invasive sleeve lobectomy to reduce complications and speed recovery while maintaining cancer control.
How similar studies have gone: Smaller single-center series and case reports have shown that minimally invasive sleeve lobectomy can be feasible and safe in selected patients, but robust multicenter data after neoadjuvant therapy remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed NSCLC * Undergoing sleeve lobectomy with curative intent * Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.) * Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy * Availability of complete perioperative and follow-up data (minimum 12-month follow-up or until death) * Signed informative consent Exclusion Criteria: * Sublobar resections (e.g., segmentectomy) or pneumonectomy * Absence of neoadjuvant therapy * Purely diagnostic surgical procedures * Incomplete medical records or lost to follow-up * Metastatic (stage IV) disease at time of surgery
Where it's running
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Xinghua Cheng, M.D., Ph.D.
- Email: chengxinghua_001@163.com
- Phone: 86+17701681215
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma
This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.